

Article 31

EPO - DG 1

-27-

14. 07. 1998

Claims

1. A vaccine comprising an antigen and a fatty acid or fatty acid peptide carrier compound which are directly or indirectly linked by a thioester or a disulphide bond that is labile and dissociates under certain physiological conditions.

2. A vaccine according to claim 1 in which said antigen dissociates from said carrier compound after the vaccine or preparation has been administered.

3. A vaccine according to claim 1 or 2 in which said antigen is a protein, a polypeptide, a synthetic peptide, a carbohydrate, or a hapten.

4. A vaccine according to claim 3 in which the antigen is a synthetic peptide.

5. A vaccine according to any one of claims 1-4 in which the fatty acid is palmitic acid.

6. A vaccine according to claim 4 or 5 in which the synthetic peptide essentially consists of the amino acid sequence /EHWSYGLRPGQHWSYGLRPG.

7. A vaccine according to claim 4 or 5 in which the synthetic peptide essentially consists of the amino acid sequence SDGAVQPDGGQPAVRNERATG.

8. A vaccine according to claim 4 or 5 in which the synthetic peptide essentially consists of the amino acid sequence RAISSWKQRNRWEWPRD.

9. A vaccine according to any one of claims 1-4 in which the antigen is a peptide and the carrier compound is another copy of said peptide coupled to a fatty acid.

10. A vaccine according to claim 9 in which the carrier compound is an N-palmitoylated peptide.

11. A vaccine according to claim 9 or 10 in which the peptide essentially consists of the amino acid sequence SDGAVQPDGGQPAVRNERATG.

a 12 A vaccine preparation according to ~~any of claims 1-11~~
a together with ^{pharmaceutically} ~~pharmacautically~~ acceptable compound or
adjuvant.

SUB
D8

13 A composition comprising a synthetic peptide linked
5 with a thioester bond to a fatty acid.

14 A composition according to claim 13 wherein the fatty
acid is palmitic acid.

a 15 A composition according to claim 13 ~~or 14~~ wherein the
peptide is selected from the group consisting of
10 /EHWSYGLRPGQHWSYGLRPG, SDGAVQPDGGQPAVRNERATG and
RAISSWKQRNRWEWPRD.

SUB
B3

16 A composition comprising a synthetic peptide linked
with a disulfide bond to a carrier compound comprising a
fatty acid linked to another copy of said synthetic peptide.

15 17 A composition according to claim 16 wherein the fatty
acid is palmitic acid.

a 18 A composition according to claim 16 ~~or 17~~ wherein the
peptide is selected from the group consisting of
/EHWSYGLRPGQHWSYGLRPG, SDGAVQPDGGQPAVRNERATG and
RAISSWKQRNRWEWPRD.

SUB
B4

19 A method for producing an immunogenic preparation
comprising linking a synthetic peptide with a fatty acid or
fatty acid peptide carrier compound via a thioester or
disalphide bond that is labile and dissociates under
25 physiological conditions.

SUB
D10

20 A method according to claim 19 wherein the fatty
acid is palmitic acid.

a 21 A method according to claim 19 ~~or 20~~ wherein the
peptide is selected from the group consisting of
/EHWSYGLRPGQHWSYGLRPG SDGAVQPDGGQPAVRNERATG and
RAISSWKQRNRWEWPRD.

SUB
B5

22 An immunogenic preparation obtainable by a method
a according to ~~any of claims 19-21.~~

claim 19

-29-

23 A vaccine comprising an immunogenic preparation
according to claim 22 together with pharmaceutically
acceptable compound or adjuvant.

664050-6004260

AMENDED SHEET
IPEA/EP